Drugs / CD30.CAR-T
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05352828 | Jul 2022 → Dec 2025 overdue | classic Hodgkin lymphoma | Tessa Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04526834 | Sep 2021 → Nov 2022 overdue | anaplastic large cell lymphoma, peripheral T-cell lymphoma, not otherwise specified, primary mediastinal large B-cell lymphoma | Tessa Therapeutics | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05320081 | Nov 2021 → Dec 2023 | lymphoma | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2 | NCT04268706 | Feb 2021 → May 2025 overdue | classic Hodgkin lymphoma | Tessa Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD30.CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04268706 ↗ |
| Modality | Cell therapy | “CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T)” NCT04268706 ↗ |
| Route | Intravenous | “single IV infusion” NCT04268706 ↗ |